SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiological Tech (NTII)
NTII 0.00010000.0%Mar 7 3:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JMarcus who wrote (1188)4/28/2003 6:30:16 PM
From: John McCarthy  Read Replies (2) of 1494
 
Hi Marc

I'm a scardy cat and until Frx releases a press release
saying the DN p=thing is statistically yada,yada,yada
I'm hiding under my blanket.

Some of the Yahoo clan say the volume level indicates
that the news is "out". But I can't buy that.
I think Frx is too cool for that to happen.

Can I hit you with a curve-ball question?

Ever here of this guy:phenoxodiol?

The short back-ground is its by NVGN and its
being checked-out by Yale. Chemo-resistent
ovarian cancer.

I'm thinking of doing a NVGN_Miscellaneous thread
to track information on it - but the stuff out
there *ain't* as robust as Memantine.

I think I know you follow cancer drugs - so I was
just wondering if you bumped up against it.

Any tidbits appreciated .....

As for Memantine, if the DN release is positive
there's really nothing left to say .....
all the arguments will be about the penetration rate.

I don't know shit from shinola but I'd bet 1,000
shares that if Paul Freiman wenting looking for companies
awhile back - his first stop would have been AXYX.

And I'm still hoping that happens.

They may have a better mouse-trap than Aricept but
even if they do - they've got a tough road in front
of them.

regards,
John
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext